中信里昂此前发布研报认为，2025年是科笛的关键商业年，因为预计将在未来12个月内陆续推出三个核心产品CU-40102、CU-10201及CU-30101，而这些产品的独特定位和先发优势，应可支持指数级的增长前景。CUTIA-B (02487) rose over 4%, as of the time of writing, up 4.14%, priced at 9.8 HKD, with a transaction amount of 4.0826 million HKD.
According to Zhitong Finance APP, CUTIA-B (02487) rose over 4%, as of the time of writing, up 4.14%, priced at 9.8 HKD, with a transaction amount of 4.0826 million HKD.
On the news front, CUTIA-B announced that the group's CU-10201 (4% minocycline foam) has obtained marketing approval from the National Medical Products Administration of the People's Republic of China (China). The indication for CU-10201 is the treatment of moderate to severe non-nodular acne and is suitable for use in children aged nine and above and adult patients.
Citi Research previously released a Research Report believing that 2025 is a crucial commercial year for CUTIA, as three core products CU-40102, CU-10201, and CU-30101 are expected to be launched successively within the next 12 months, and the unique positioning and first-mover advantage of these products should support an Index-level growth outlook.